Brief: Syndax Announces FDA Priority Review Of sNDA For Revuforj In Relapsed Or Refractory mNPM1 Acute Myeloid Leukemia
24/06/2025 21:14
June 24 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O: SYNDAX ANNOUNCES FDA PRIORITY REVIEW OF SNDA FOR REVUFORJ® (REVUMENIB) IN RELAPSED OR REFRACTORY MNPM1 ACUTE MYELOID LEUKEMIA SYNDAX PHARMACEUTICALS INC - PDUFA ACTION DATE SET FOR OCTOBER 25, 2025 Source text: ID:nGNX5ZsmN6 Further company coverage: SNDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million